Duncan John Higgons - Director, Jounce Therapeutics, Inc

As of June 22, 2021


Duncan John Higgons Net Worth

  • Net worth is estimated to be at least $27.1M
  • Owns at least 9,713 units of Jounce Therapeutics, Inc stock
  • Sold an estimated value of $39.3K in the last 4 years at Jounce Therapeutics, Inc

Duncan John Higgons Trading

  • Largest purchase of shares was 6,700 units , worth over $107.2K on February 2, 2017
  • Largest sale of shares was 1,700 units , worth over $20.22K on January 22, 2021
  • In total has made about 10 transactions over 4 years
  • Usually trades in June, with the busiest year in 2021
Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1

Duncan John Higgons Mailing Address

  • Mailing address is C/o Agios Pharmaceuticals, Inc. 38 Sidney Street, 2nd Floor Cambridge MA 02139 MA

Jounce Therapeutics, Inc Executive Compensation

Name
Year
Salary
Bonus
Stock Awards
Option Awards
Other Compensation
Total
Richard Murray, Ph.D., 2020 $565,100 $310,810 $491,316 $627,312 $8,946 $2,003,484
Richard Murray, Ph.D., 2019 $540,800 $295,500 $275,044 $348,665 $8,796 $1,468,805
Hugh M. Cole 2020 $420,000 $212,520 $196,500 $250,908 $8,808 $1,088,736
Hugh M. Cole 2019 $401,700 $153,700 $97,900 $124,115 $5,709 $783,124
Kim C. Drapkin 2020 $398,400 $175,300 $174,885 $223,308 $8,688 $980,581
Kim C. Drapkin 2019 $381,200 $145,800 $97,900 $124,115 $8,796 $757,811
No matching records found

Source: https://www.sec.gov/Archives/edgar/data/1640455/000164045521000078/jnce042621def14a.htm

Jounce Therapeutics, Inc Insider Trading

  • The most recent transaction was 1,900,000 units sold on November 16, 2021 by Third Rock Ventures Iii Lp, Third Rock Ventures GP Iii Lp, Trv GP Iii Llc, Kevin Starr, Robert Tepper and Mark Levin worth over $15.92M
  • In the last 4 years, insiders at Jounce Therapeutics, Inc sold an estimated value of $41.96M and bought an estimated value of $10.7M
  • The most active traders are Elizabeth Trehu, Chief Medical Officer,  Kimberlee C Drapkin, CFO and Treasurer,  and Cary Pfeffer, Director
  • Insider trading is most common in June, with the busiest year in 2021

Jounce Therapeutics, Inc. Insider Trades

Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1